#JiangsuHengruiPharma has chalked up a first-in-class approval for retlirafusp alfa, a #bifunctionaldrug that targets #PDL1 and #TGFbeta, as a treatment for advanced #gastriccancer.

pharmaphorum.com/news/hengrui...